{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:57:18Z","timestamp":1781643438987,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Enzyme replacement therapies (ERTs) approved for Fabry disease require infusions every 2 weeks (E2W). Pegunigalsidase alfa, a PEGylated ERT with a prolonged half-life vs. other ERTs, may allow extension of the dosing interval to every 4 weeks (E4W).<\/jats:p>\n                    <jats:p>BRIGHT F51 (NCT03614234) is an ongoing phase III, open-label extension study evaluating long-term efficacy and safety of pegunigalsidase alfa 2 mg\/kg E4W in adults with Fabry disease previously treated with agalsidase alfa or beta E2W for \u2265 3 years who completed one year of pegunigalsidase alfa treatment in the BRIGHT study. This interim analysis reports results following 3\u20135 years of treatment (cutoff date December 31, 2022).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-nine patients were enrolled. Median (interquartile range [IQR]) annualized eGFR slope during treatment was \u20122.2 (\u20122.9; \u20121.1) mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      \/year (males: \u20122.4 [\u20122.9; \u20121.0,\n                      <jats:italic>n =<\/jats:italic>\n                      23]; females: \u20121.8 [\u20122.4; \u20121.3,\n                      <jats:italic>n<\/jats:italic>\n                      = 6]; anti-drug antibody [ADA]-positive: \u20122.6 [\u20124.0; \u20121.7,\n                      <jats:italic>n =<\/jats:italic>\n                      9 all male]; ADA-negative: \u20121.8 [\u20122.7; \u20120.6,\n                      <jats:italic>n =<\/jats:italic>\n                      20]). Median (IQR) change in plasma lyso-Gb3 from baseline to Week 208 was 3.2 (\u20123.9; 8.5,\n                      <jats:italic>n =<\/jats:italic>\n                      17) nM in males; concentrations remained low and stable in females. Overall, 51\/477 treatment-emergent adverse events in 13 patients (45%) were considered treatment-related (all mild\/moderate). Nine patients (31%) experienced mild\/moderate infusion-related reactions. One patient developed transient\n                      <jats:italic>de novo<\/jats:italic>\n                      ADAs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Long-term treatment with pegunigalsidase alfa 2 mg\/kg E4W was well-tolerated and maintained disease stability, especially in females and ADA-negative males; more data are needed to better understand outcomes in ADA-positive males. Clinical outcomes should be closely monitored during E4W treatment. The final results of this extension study will further assess the feasibility of this dosing regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration details<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov, NCT03614234. Registered July 30, 2018;\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03614234\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT03614234<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04303-8","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T08:34:23Z","timestamp":1773995663000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study"],"prefix":"10.1186","volume":"21","author":[{"given":"Myrl","family":"Holida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ale\u0161","family":"Linhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"T\u00f8ndel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derralynn","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Warnock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Eyskens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Deegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Feldt-Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Goker-Alpan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Piotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Fichera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Chertkoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Waldek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2033-6129","authenticated-orcid":false,"given":"John A.","family":"Bernat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"4303_CR1","unstructured":"Mehta A, Hughes DA. Fabry disease. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(\u00ae). edn. Seattle WA: University of Washington; 2002 [updated April 11, 2024]."},{"key":"4303_CR2","doi-asserted-by":"crossref","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;530.","DOI":"10.1186\/1750-1172-5-30"},{"issue":"3","key":"4303_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","volume":"124","author":"C Wanner","year":"2018","unstructured":"Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab. 2018;124(3):189\u2013203.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"4303_CR4","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/ijms22010206","volume":"22","author":"O Azevedo","year":"2020","unstructured":"Azevedo O, Gago MF, Miltenberger-Miltenyi G, Sousa N, Cunha D. Fabry disease therapy: state-of-the-art and current challenges. Int J Mol Sci. 2020;22(1):206.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4303_CR5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","volume":"52","author":"DP Germain","year":"2015","unstructured":"Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52(5):353\u201358.","journal-title":"J Med Genet"},{"issue":"5","key":"4303_CR6","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007;18(5):1547\u201357.","journal-title":"J Am Soc Nephrol"},{"issue":"21","key":"4303_CR7","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA, 3rd, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285(21):2743\u201349.","journal-title":"JAMA"},{"issue":"4","key":"4303_CR8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","volume":"54","author":"DA Hughes","year":"2017","unstructured":"Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2017;54(4):288\u201396.","journal-title":"J Med Genet"},{"key":"4303_CR9","unstructured":"Shire Human Genetic Therapies AB. Replagal: summary of product characteristics. 2022."},{"key":"4303_CR10","unstructured":"Genzyme Corporation. Fabrazyme (agalsidase beta) for injection, for intravenous use: prescribing information. 2024."},{"issue":"1","key":"4303_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13023-022-02392-9","volume":"17","author":"M Beck","year":"2022","unstructured":"Beck M, Ramaswami U, Hernberg-St\u00e5hl E, Hughes DA, Kampmann C, Mehta AB, et al. Twenty years of the Fabry outcome survey (FOS): insights, achievements, and lessons learned from a global patient registry. Orphanet J Rare Dis. 2022;17(1):238.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"4303_CR12","doi-asserted-by":"publisher","first-page":"107603","DOI":"10.1016\/j.ymgme.2023.107603","volume":"139","author":"C Wanner","year":"2023","unstructured":"Wanner C, Ortiz A, Wilcox WR, Hopkin RJ, Johnson J, Ponce E, et al. Global reach of over 20 years of experience in the patient-centered Fabry registry: advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community. Mol Genet Metab. 2023;139(3):107603.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"4303_CR13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1681\/ASN.2014121226","volume":"27","author":"M Lenders","year":"2016","unstructured":"Lenders M, Stypmann J, Duning T, Schmitz B, Brand SM, Brand E. Serum-mediated inhibition of enzyme replacement therapy in Fabry disease. J Am Soc Nephrol. 2016;27(1):256\u201364.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"4303_CR14","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","volume":"66","author":"GE Linthorst","year":"2004","unstructured":"Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int. 2004;66(4):1589\u201395.","journal-title":"Kidney Int"},{"key":"4303_CR15","unstructured":"Amicus Therapeutics. Galafold: summary of product characteristics. 2023."},{"key":"4303_CR16","unstructured":"Amicus Therapeutics. Galafold (migalastat) capsules, for oral use: prescribing information. 2025."},{"key":"4303_CR17","unstructured":"Chiesi USA. Inc. Elfabrio (pegunigalsidase alfa-iwxj) injection, for intravenous use: prescribing information. 2024."},{"key":"4303_CR18","unstructured":"Chiesi Farmaceutici S.p.A. Elfabrio: summary of product characteristics. 2024."},{"issue":"2","key":"4303_CR19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ymgme.2014.08.002","volume":"114","author":"T Kizhner","year":"2015","unstructured":"Kizhner T, Azulay Y, Hainrichson M, Tekoah Y, Arvatz G, Shulman A, et al. Characterization of a chemically modified plant cell culture expressed human \u03b1-galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metab. 2015;114(2):259\u201367.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"4303_CR20","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/jimd.12080","volume":"42","author":"R Schiffmann","year":"2019","unstructured":"Schiffmann R, Goker-Alpan O, Holida M, Giraldo P, Barisoni L, Colvin RB, et al. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year phase I\/II clinical trial. J Inherit Metab Dis. 2019;42(3):534\u201344.","journal-title":"J Inherit Metab Dis"},{"key":"4303_CR21","doi-asserted-by":"crossref","unstructured":"Lenders M, Pollmann S, Terlinden M, Brand E. Pre-existing anti-drug antibodies in Fabry disease show less affinity for pegunigalsidase alfa. Mol Ther Methods Clin Dev. 2022;26:323\u201330.","DOI":"10.1016\/j.omtm.2022.07.009"},{"issue":"12","key":"4303_CR22","doi-asserted-by":"publisher","first-page":"100968","DOI":"10.1016\/j.gim.2023.100968","volume":"25","author":"D Hughes","year":"2023","unstructured":"Hughes D, Gonzalez D, Maegawa G, Bernat JA, Holida M, Giraldo P, et al. Long-term safety and efficacy of pegunigalsidase alfa: a multicenter 6-year study in adult patients with Fabry disease. Genet Med. 2023;25(12):100968.","journal-title":"Genet Med"},{"issue":"1","key":"4303_CR23","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s13023-023-02937-6","volume":"18","author":"A Linhart","year":"2023","unstructured":"Linhart A, Dost\u00e1lov\u00e1 G, Nicholls K, West ML, T\u00f8ndel C, Jovanovic A, et al. Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase III open-label study. Orphanet J Rare Dis. 2023;18(1):332.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"4303_CR24","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1136\/jmg-2023-109445","volume":"61","author":"EL Wallace","year":"2024","unstructured":"Wallace EL, Goker-Alpan O, Wilcox WR, Holida M, Bernat J, Longo N, et al. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study. J Med Genet. 2024;61(6):520\u201330.","journal-title":"J Med Genet"},{"key":"4303_CR25","doi-asserted-by":"crossref","unstructured":"Holida M, Linhart A, Pisani A, Longo N, Eyskens F, Goker-Alpan O, et al. A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies. J Inherit Metab Dis. 2025;48(1):e12795.","DOI":"10.1002\/jimd.12795"},{"key":"4303_CR26","unstructured":"Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio\u00ae (pegunigalsidase alfa). Press release, 9 March 2026. https:\/\/www.chiesi.uk.com\/media\/press-releases\/chiesi-global-rare-diseases-protalix.\u00a0Accessed 11 Mar 2026."},{"issue":"3","key":"4303_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10865-007-9147-y","volume":"31","author":"KS Ingersoll","year":"2008","unstructured":"Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008;31(3):213\u201324.","journal-title":"J Behav Med"},{"key":"4303_CR28","doi-asserted-by":"crossref","unstructured":"Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone. 2006;38(4 Suppl 1):S2\u20136.","DOI":"10.1016\/j.bone.2006.01.150"},{"issue":"9","key":"4303_CR29","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"key":"4303_CR30","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012;2(5):337\u2013414."},{"issue":"451","key":"4303_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/08035320600618825","volume":"95","author":"M Beck","year":"2006","unstructured":"Beck M. The Mainz Severity Score Index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry disease. Acta Paediatr Suppl. 2006;95(451):43\u201346.","journal-title":"Acta Paediatr Suppl"},{"issue":"4","key":"4303_CR32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","volume":"65","author":"C Whybra","year":"2004","unstructured":"Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E, et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet. 2004;65(4):299\u2013307.","journal-title":"Clin Genet"},{"key":"4303_CR33","doi-asserted-by":"crossref","unstructured":"Cleeland CS. Brief Pain Inventory Short Form (BPI-SF). 1991. https:\/\/www.mdanderson.org\/documents\/Departments-and-Divisions\/Symptom-Research\/BPI_UserGuide.pdf. Accessed 2 Jan 2025.","DOI":"10.1037\/t04175-000"},{"key":"4303_CR34","unstructured":"EuroQol Research Foundation. EQ-5D-5L user guide. 2019. https:\/\/euroqol.org\/publications\/user-guides\/. Accessed 2 Jan 2025."},{"key":"4303_CR35","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE). https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed 16 Dec 2024."},{"key":"4303_CR36","doi-asserted-by":"crossref","unstructured":"Holida M, Linhart A, Pisani A, Longo N, Eyskens F, Goker-Alpan O, et al. A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies (supporting information, appendix S1). J Inherit Metab Dis. 2025;48(1):e12795.","DOI":"10.1002\/jimd.12795"},{"issue":"9","key":"4303_CR37","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","volume":"1802","author":"SM Rombach","year":"2010","unstructured":"Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, et al. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta. 2010;1802(9):741\u201348.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"4303_CR38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","volume":"1812","author":"MJ van Breemen","year":"2011","unstructured":"van Breemen MJ, Rombach SM, Dekker N, Poorthuis BJ, Linthorst GE, Zwinderman AH, et al. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim Biophys Acta. 2011;1812(1):70\u201376.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"4303_CR39","doi-asserted-by":"publisher","first-page":"109110","DOI":"10.1016\/j.ymgme.2025.109110","volume":"145","author":"U Ramaswami","year":"2025","unstructured":"Ramaswami U, West ML, Tylee K, Castillon G, Braun A, Ren M, et al. The use and performance of lyso-Gb3 for the diagnosis and monitoring of Fabry disease: a systematic literature review. Mol Genet Metab. 2025;145(2):109110.","journal-title":"Mol Genet Metab"},{"key":"4303_CR40","unstructured":"National Kidney Foundation. K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(Suppl 1):S1\u2013266."},{"key":"4303_CR41","doi-asserted-by":"crossref","unstructured":"Batista JL, Hariri A, Maski M, Richards S, Gudivada B, Raynor LA, et al. Reduction in kidney function decline and risk of severe clinical events in agalsidase beta-treated Fabry disease patients: a matched analysis from the Fabry registry. Clin Kidney J. 2024;17(8):sfae194.","DOI":"10.1093\/ckj\/sfae194"},{"issue":"7","key":"4303_CR42","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","volume":"24","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transpl. 2009;24(7):2102\u201311.","journal-title":"Nephrol Dial Transpl"},{"issue":"12","key":"4303_CR43","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.2215\/CJN.04340510","volume":"5","author":"C Wanner","year":"2010","unstructured":"Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, Linthorst GE, et al. Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry registry. Clin J Am Soc Nephrol. 2010;5(12):2220\u201328.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"4303_CR44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/ndt\/gfad164","volume":"39","author":"A Pisani","year":"2023","unstructured":"Pisani A, Pieruzzi F, Cirami CL, Riccio E, Mignani R. Interpretation of GFR slope in untreated and treated adult Fabry patients. Nephrol Dial Transpl. 2023;39(1):18\u201325.","journal-title":"Nephrol Dial Transpl"},{"issue":"12","key":"4303_CR45","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1681\/ASN.2018070740","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Neu\u00dfer LP, Rudnicki M, Nordbeck P, Canaan-K\u00fchl S, Nowak A, et al. Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease. J Am Soc Nephrol. 2018;29(12):2879\u201389.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"4303_CR46","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, et al. Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat. N Engl J Med. 2016;375(6):545\u201355.","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"4303_CR47","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","volume":"120","author":"A Nowak","year":"2017","unstructured":"Nowak A, Mechtler TP, Desnick RJ, Kasper DC. Plasma lyso-Gb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. Mol Genet Metab. 2017;120(1\u20132):57\u201361.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"4303_CR48","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1136\/jmg.2004.025791","volume":"42","author":"B Hoffmann","year":"2005","unstructured":"Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R. Effects of enzyme replacement therapy on pain and health-related quality of life in patients with Fabry disease: data from FOS (Fabry outcome survey). J Med Genet. 2005;42(3):247\u201352.","journal-title":"J Med Genet"},{"issue":"7","key":"4303_CR49","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s10198-022-01541-y","volume":"24","author":"M Meregaglia","year":"2023","unstructured":"Meregaglia M, Nicod E, Drummond M. The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review. Eur J Health Econ. 2023;24(7):1151\u2013216.","journal-title":"Eur J Health Econ"},{"issue":"3","key":"4303_CR50","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ymgme.2011.12.006","volume":"105","author":"WR Wilcox","year":"2012","unstructured":"Wilcox WR, Linthorst GE, Germain DP, Feldt-Rasmussen U, Waldek S, Richards SM, et al. Anti-\u03b1-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry registry. Mol Genet Metab. 2012;105(3):443\u201349.","journal-title":"Mol Genet Metab"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04303-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04303-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04303-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:33:16Z","timestamp":1781641996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04303-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4303"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04303-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ethical principles of the Helsinki Declaration (1975, and as revised in 2000), Good Clinical Practice guidelines, and the ethical standards of the responsible committee on human experimentation (institutional and national). Ethics approval was obtained from the responsible committees at each participating site: Belgium (Ethisch Comit\u00e9 UZA), Czech Republic (Eticka komise Vseobecne fakultni nemocnice v Praze), Denmark (De Videnskabsetiske Komiteer for Region Hovedstaden Kongens V\u00e6nge 2, EC Commit\u00e9), Italy (Comitato Etico Territoriale Campania 3), Norway (REK Midt), the United Kingdom (West of Scotland REC 1), and the United States of America (WCG IRB and University of Utah Institutional Review Board). Informed consent for being included in the study was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MH has received speaker\u2019s honoraria from Chiesi. AL has received grants\/contracts from Sanofi; consulting fees from Amicus Therapeutics, Chiesi, and Sanofi; payment\/honoraria from Amicus Therapeutics, Chiesi, Sanofi, and Takeda; and support for meeting attendance\/travel from Amicus Therapeutics, Chiesi, and Sanofi; and has participated in advisory boards for Amicus Therapeutics and Sanofi. NL has received grants for clinical trials from Amicus Therapeutics, Chiesi and Protalix Biotherapeutics, Sanofi, and Takeda; consulting fees from Amicus Therapeutics, Protalix Biotherapeutics, Sanofi, and Takeda; and travel support and speaker\u2019s honoraria for presentations from Chiesi. EW has received grants for clinical trials from Chiesi, Idorsia Pharmaceuticals, Sanofi, and uniQure; consulting fees from Chiesi, Sanofi, and Sangamo Therapeutics; speaker\u2019s honoraria from Chiesi, Natera, and Sanofi; and support for meeting attendance\/travel from Chiesi and Sanofi. CT has received contracts for clinical trials on Fabry disease from Chiesi, Idorsia Pharmaceuticals, and Sanofi; consulting fees from AceLink Therapeutics, Amicus Therapeutics, Chiesi, and Sanofi; speaker\u2019s honoraria from Amicus Therapeutics, Chiesi, and Sanofi; and support for meeting attendance\/travel from Chiesi and Sanofi; and has participated in advisory boards from Amicus Therapeutics, Chiesi, and Sanofi. DH has received grants\/contracts from Chiesi; consulting fees from Amicus Therapeutics, Chiesi, Idorsia Pharmaceuticals, Sangamo Therapeutics, Sanofi, Spur, and Takeda; and support for meeting attendance\/travel and speaker\u2019s honoraria from Amicus Therapeutics, Chiesi, Sanofi, and Takeda; and has participated in advisory boards for uniQure. DGW has received travel\/accommodation support for lectures from Chiesi and consulting fees from AceLink Therapeutics, Crosswalk Therapeutics, Relay Therapeutics, and Vera Therapeutics. AP has no conflicts of interest to report. FE has received consulting fees, travel support, and fees for participation in advisory boards from Chiesi. PD has received support for meeting attendance\/travel from Chiesi, and speaker\u2019s payment\/honoraria and consulting fees from Chiesi and Protalix Biotherapeutics. UFR has received travel grants and lecture fees and participated in advisory boards for Chiesi, Freeline, Sanofi, Shire, and Takeda, and received research grants from Genzyme and Shire. UFR\u2019s research salary was sponsored by a grant from Kirsten and Freddy Johansen\u2019s Fund. OGA has received reimbursements for grants\/contracts related to Fabry disease from Chiesi and Sanofi and honoraria for lectures\/presentations and travel support from Chiesi. AM has received payment\/honoraria from Amgen, AstraZeneca, Bayer, and Sanofi; and consulting fees from Amgen, Chiesi, and Sanofi; and has participated in advisory boards for Chiesi and Sanofi. GP, MW, and VF are full-time employees of Chiesi. RC was a full-time employee of Protalix Biotherapeutics at the time of study conduct and analysis and is now a consultant to Protalix Biotherapeutics; and owns stocks\/stock options in Protalix Biotherapeutics. SW has received consulting fees from Protalix Biotherapeutics. WRW has received research grants from Amicus Therapeutics; contracts for clinical trials from 4D Molecular Therapeutics, Alexion Pharmaceuticals, Amgen, Amicus Therapeutics, BioMarin Pharmaceutical, Sangamo Therapeutics, Sanofi, Takeda, and uniQure; consulting fees from Spark Therapeutics and uniQure; and payment for an expert testimony from a legal firm representing Sanofi; has participated in advisory boards for BioMarin Pharmaceutical and Sanofi; and is a member of the Board of Directors of the American College of Medical Genetics. JAB has received grants for clinical trials from AVROBIO, BioMarin Pharmaceutical, Chiesi, Denali Therapeutics, Idorsia Pharmaceuticals, Pfizer, Protalix Biotherapeutics, Sangamo Therapeutics, Sanofi, Takeda, and Travere Therapeutics; consulting fees for advisory board meetings from Chiesi and Mirum Pharmaceuticals; support for meeting attendance\/travel from Chiesi; and a speaker\u2019s honorarium from the Fabry Support & Information Group.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}